ZA937553B - Clot directed anticoagulant process for making same and methods of use - Google Patents

Clot directed anticoagulant process for making same and methods of use

Info

Publication number
ZA937553B
ZA937553B ZA937553A ZA937553A ZA937553B ZA 937553 B ZA937553 B ZA 937553B ZA 937553 A ZA937553 A ZA 937553A ZA 937553 A ZA937553 A ZA 937553A ZA 937553 B ZA937553 B ZA 937553B
Authority
ZA
South Africa
Prior art keywords
clot
directed
methods
making same
anticoagulant process
Prior art date
Application number
ZA937553A
Inventor
Paul Eisenberg
Dennis Brian Rylatt
Carmel Judith Hillyard
Peter Gregory Bundesen
Original Assignee
Agen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agen Ltd filed Critical Agen Ltd
Publication of ZA937553B publication Critical patent/ZA937553B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA937553A 1992-10-12 1993-10-12 Clot directed anticoagulant process for making same and methods of use ZA937553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPL523492 1992-10-12

Publications (1)

Publication Number Publication Date
ZA937553B true ZA937553B (en) 1994-05-03

Family

ID=3776468

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA937553A ZA937553B (en) 1992-10-12 1993-10-12 Clot directed anticoagulant process for making same and methods of use

Country Status (3)

Country Link
EP (1) EP0668875A4 (en)
WO (1) WO1994009034A1 (en)
ZA (1) ZA937553B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002318960B2 (en) * 2001-06-26 2008-05-15 Agen Biomedical Limited Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
CN101124248A (en) * 2004-08-11 2008-02-13 特鲁比昂药品公司 Binding domain fusion proteins
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2510943B1 (en) * 2006-02-06 2016-04-20 The Burnham Institute for Medical Research Methods and compositions related to targeting tumors and wounds
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single-chain multivalent binding proteins with effector function
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
BR112019010034A2 (en) 2016-11-16 2019-09-03 Bayer Healthcare Llc targeted red blood cell factor viii and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
CA2051436A1 (en) * 1989-04-03 1990-10-04 Christoph Bode Platelet specific immunoconjugates
NL8901102A (en) * 1989-05-01 1990-12-03 Tno ANTIBODIES AGAINST FIBRINE; IMMUNOGENIC PEPTIDES SUITABLE FOR THE PREPARATION OF THE ANTIBODIES, METHOD FOR DETERMINING FIBRIN AND PHARMACEUTICAL PREPARATION BASED ON THE ANTIBODIES.
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
AU636909B2 (en) * 1989-08-24 1993-05-13 Australian Nuclear Science & Technology Organisation Radio-labelled antibodies for imaging
WO1991016353A1 (en) * 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
JPH07501795A (en) * 1991-10-01 1995-02-23 ザ・ジェネラル・ホスピタル・コーポレーション Activation-dependent proteins and their antibodies expressed on the surface of activated platelets

Also Published As

Publication number Publication date
WO1994009034A1 (en) 1994-04-28
EP0668875A1 (en) 1995-08-30
EP0668875A4 (en) 1999-05-26

Similar Documents

Publication Publication Date Title
EP0486006A3 (en) Absorbent article and method of making same
GB2236485B (en) Tampon and method of making the same
GB9015366D0 (en) Controlled rate adsorbent unit and method of fabrication thereof
HK1007946A1 (en) Article gripping means and method of making same
EP0434258A3 (en) Adhesive dressing assemblies and methods of dressing
PL286707A1 (en) Method of obteining tetraniture
ZA937553B (en) Clot directed anticoagulant process for making same and methods of use
EP0423513A3 (en) Laserwafer and method of producing same
EP0491293A3 (en) Polyolefin articles and methods of making same
PL320065A1 (en) Disposable filters and method of making them
GB2237299B (en) Trim and method of use
IL93857A0 (en) Substituted isoquinolines and methods of using same
PL300549A1 (en) Structural component and method of making same
EP0472422A3 (en) Oligohexafluoropropylene compounds and methods of making them
GB8923571D0 (en) Connecting means and method of use thereof
EP0430579A3 (en) Fluoroaliphatic-group-substituted esters and method of making the same
EP0429009A3 (en) Shaped articles and method of making same
SU1670858A1 (en) Method of blood drawing
GB9322085D0 (en) Smoking articles and method of making them
GB8916394D0 (en) Method of treatment
GB9421020D0 (en) Smoking articles and method of making them
IL90805A0 (en) Catheter and method of using same
PL284235A1 (en) Sorbent and method of obtaining same
IL93334A0 (en) Handbrush and method of manufacture thereof
ZA90713B (en) Handbrush and method of manufacture thereof